China (Mainland)
Tenofovir Alafenamide Hemifumarate TAF factory in China 1392275-56-7 CAS NO.1392275-56-7
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- Tenofovir Alafenamide Hemifumarate TAF factory
- 1392275-56-7 in China
- 1392275-56-7
Quick Details
- ProName: Tenofovir Alafenamide Hemifumarate TAF...
- CasNo: 1392275-56-7
- Molecular Formula: C21H29O5N6P·1/2(C4H4O4)
- Appearance: White to off white powder.
- Application: HIV, HBV
- DeliveryTime: 10 days after ordering
- PackAge: Two-layer LDPE bag and All Paper Barre...
- Port: Any port in China
- ProductionCapacity: 10 Metric Ton/Year
- Purity: 98.0%~102.0% (on the anhydrous basis)
- Storage: 2~8°C
- Transportation: as per request
- LimitNum: 1 Kilogram
Superiority
Tenofovir Alafenamide Hemifumarate TAF factory in China1392275-56-7
An overview of the
Gilead's new drug, Vemlidy (Tenofovir alafialamine fumarate, 25mg, qD), was approved by the U.S. FDA to compensate for chronic hepatitis B virus infection in patients with liver disease. Vemlidy is an innovation of targeting drug tenofovir ago, with previous products 300 mg of Viread (tenofovir ester of fumaric acid salt, tenofovirdisoproxilfumarate), compared to only need less than one over ten of the dose can obtain similar antiviral activity. Clinical data showed that Vemlidy had better plasma stability and was able to deliver tenofovir to hepatocytes more effectively. Because of the lower dose, VemlidyChemicalbook can improve the safety risk of kidney and bone in patients.
role
Tenofovir alafenamide (TAF), an oral nucleoside transcriptase inhibitor developed by Gilead, is another prodrug of tenofovir disoproxil fumarate (TDF), developed for hepatitis B virus infection (HBV) and acquired immune syndrome (HIV).
use
Tenofovir alafine fumarate can be used as a solvent, catalyst for alkylation, esterification and polymerization reactions. 99% of the products are mainly used in medicine, 70% of the products are mainly used in electroplating industry. Nutritional drugs, combined with a low-protein diet, are the core drugs for the prevention and treatment of damage caused by protein metabolism disorder caused by chronic renal insufficiency, chronic renal insufficiency and wasting malnutrition.
LONZEAL Pharmaceuticals was founded in 2006 and has become a leading manufacturing company covering finished formulation, active pharmaceutical ingredients and advanced intermediates, where ICH guidelines have been strictly applied in the whole chain of R&D, manufacturing process and quality management.
LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.
We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.
Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.
LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.
We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.
Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.
Details
A new drug called tenofovir alafenamide fumaric acid, or TAF, has emerged in recent years as antiviral drugs have been developed to treat chronic hepatitis B. The drug is an upgrade of Tenofovir Disoprox, or TDF, an oral antiviral drug already on the market.
In clinical trials, on behalf of Norfolk WeiYi phenol amine fumaric acid has been shown in dose is only one over ten of tenofovir ester doses, it has a very high antiviral properties, resistance to like tenofovir ester is very low, at the same time compared to the drug tenofovir ester has better security, to the kidney and bone fewer side effects.
Like Adefovir dipivoxil and Tenofovir dipivoxil, tenofovir dipivoxil is a nucleotide drug that was developed and patented by Gilead Sciences. Tenofovir alafenamide fumaric acid is marketed as Vemlidy.
On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved tenofovir alafialamine fumaric acid for the treatment of chronic hepatitis B in the United States.
On 19 December 2016, Japan's Ministry of Health, Labour and Welfare (MHLW) approved tenofovir alafenamide fumaric acid for the treatment of chronic hepatitis B in Japan.
On 1 September 2017, the European Medicines Agency (EMA) approved tenofovir alafialamine fumaric acid for the treatment of chronic hepatitis B in eu member states.
Although tenofovir alafenamide fumaric acid has not been marketed in China, it will provide an effective and safe drug for long-term treatment of hepatitis B patients due to its stronger antiviral effect, lower drug resistance rate and fewer side effects. At present, the relevant professional associations in Europe and the United States and other developed countries have included tenofovir alafenamine fumaric acid as a first-line antiviral drug.
Tenofovir Alafenamide fumaric acid is a reverse transcriptase inhibitor. Upon entry into liver cells, the drug can be hydrolyzed to tenofovir. Tenofovir is then phosphorylated by intracellular kinases to become pharmacologically active tenofovir diphosphate. Tenofovir diphosphate is integrated into viral DNA by HBV reverse transcriptase, which leads to the interruption of DNA chain synthesis and inhibits viral replication.
This drug is mainly used in adult chronic hepatitis B patients with active hepatitis B virus replication, continuously elevated transaminase, or liver histology showing active liver disease.